![Biomarkers in IO: Challenges and Putative Benefits of Multi-omics Technologies](https://d38uvx7mib76ry.cloudfront.net/public/images/J0RBs68rADcMMbpUvXH7jb79TetXZCOL7hQSzzoU.png)
Summary:
In this podcast, you will hear a panel discussion, moderated by Dr Theresa LaVallee, Parker Institute for Cancer Immunotherapy, from the 2021 Immuno-Oncology 360° Conference regarding pan-tumor and multi-tumor biomarker development mechanisms, multi-omic biomarkers for patient selection in solid tumor IO and evaluating single cell omics to understand the heterogeneity in immune and tumor cells.
To learn more about the Immuno-Oncology 360° Conference, please visit IO360Summit.com.
Related Podcasts
View All![Unlocking ctDNA's Potential for Prognostic Stratification, Tumor Evolution Insights & Accelerated Drug Development](https://d38uvx7mib76ry.cloudfront.net/public/images/B1auwoT8ay8rv3yuV4VCj1STzbGoy021dONMzRpa.png)
Unlocking ctDNA's Potential for Prognostic Stratification, Tumor Evolution Insights & Accelerated Drug Development
![Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process](https://d38uvx7mib76ry.cloudfront.net/public/images/AYpBueo73sCdV35PWH03VZAbzSTl5LAzpocI3Dw2.png)
Key Lessons from Manufacturing Cell-Based Immunotherapies to Accelerate Development and Process
![Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities](https://d38uvx7mib76ry.cloudfront.net/public/images/7vsSLL3HBWLTBtdS3MMK2xSWLQbAiFFpcrzUwzxk.png)
Targeting TGF Beta in IO: Mechanisms, Challenges and Opportunities
![Delivery Challenges from the Oncology Pipeline](https://d38uvx7mib76ry.cloudfront.net/public/images/KtKZ8eWZDTc3KHctMQwakc58erXkmiezGIWodFIR.png)